Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases - 24/08/11
Reprint requests: Amy S. Paller, MD, Children's Memorial Hospital Center, 2300 Children's Memorial Plaza, No. 107, Chicago, IL 60614.New York, New York, and Chicago, Illinois
Résumé |
Background |
Vitiligo is an autoimmune disorder characterized by loss of pigmentation. Phototherapy and application of topical corticosteroids are most commonly prescribed. However, these therapies are often not effective and use of corticosteroids on the face may lead to cutaneous atrophy, telangiectasia, and ocular complications.
Objective |
We sought to assess the efficacy of topical tacrolimus ointment in the treatment of pediatric vitiligo.
Methods |
A retrospective review was performed of 57 pediatric patients with vitiligo at two clinical sites. Patients were treated with tacrolimus ointment for at least 3 months. Clinical responses were documented during clinic visits, and by pretacrolimus and posttacrolimus photography.
Results |
At least partial response was noted to tacrolimus ointment on the head and neck in 89%, and on the trunk and extremities in 63% of patients. Facial vitiligo of the segmental type showed the best response rate. Two patients initially experienced burning on application.
Conclusions |
Topical tacrolimus ointment is an effective alternative therapy for childhood vitiligo, particularly involving the head and neck.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Disclosure: All of the participating physicians are involved in clinical research trials with Fujisawa Healthcare Inc for atopic dermatitis. Dr Paller is also a consultant for both Fujisawa Healthcare Inc. |
Vol 51 - N° 5
P. 760-766 - novembre 2004 Retour au numéro
Article précédent
- Digital anesthesia with epinephrine: An old myth revisited
- Aleksandar L. Krunic, Linda C. Wang, Keyoumars Soltani, Sarah Weitzul, R. Stan Taylor
- Extramammary Paget's disease: Surgical treatment with Mohs micrographic surgery
- Ali Hendi, David G. Brodland, John A. Zitelli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?